sofpironium bromide sofpironium bromide sofpironium bromide (trade name ecclock; development code bbi-4000) is a drug used to treat hyperhidrosis (excessive sweating). it was approved in japan in 2020 as a 5% gel for the treament of primary axillary hyperhidrosis (pah). sofpironium bromideclinical datatrade namesecclockother namesbbi 4000routes ofadministrationtopical gellegal statuslegal status rx-only (japan) identifiers iupac name (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide cas number1628106-94-4pubchem cid86301316chemspider52085312unii7b2y1932xukeggd10989chemblchembl3707223chemical and physical dataformulac22h32brno5molar mass470.404 g·mol−13d model (jsmol)interactive image smiles ccoc(=o)c1(cc(c1)oc(=o)(c2cccc2)(c3=cc=cc=c3)o)c. inchi inchi=1s/c22h32no5.brh/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26h,3,7-8,11-16h2,1-2h3;1h/q+1;/p-1/t19-,22+,23?;/m1./s1key:fiafmtcujcwadz-jofreboksa-m sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting m3 muscarinic receptors in eccrine glands. it is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide, meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.